ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)

Rhea-AI Summary

ChromaDex announced promising results from a clinical study on nicotinamide riboside (NR) for patients with ataxia-telangiectasia (AT), a rare neurodegenerative disorder. Conducted by Radboud University Medical Center, the study demonstrated that NR improved ataxia scores and increased immunoglobulin levels in 24 participants, including 17 children. Patients received 25mg/kg of NR daily for four months. Though results are encouraging, further research is needed to confirm the therapeutic potential of NR for AT.

Positive

• Improved ataxia scores and increased immunoglobulin G (IgG) levels in patients.
• First NR clinical trial to include participants under 18, indicating potential for pediatric applications.
• The study is consistent with previous preclinical research supporting NR effectiveness.

Negative

• None.

New clinical research in ataxia-telangiectasia (AT) patients finds nicotinamide riboside (NR) improved Ataxia scores and increased antibody levels

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders, conducted by Michèl A.A.P. Willemsen MD, PhD of Radboud University Medical Center. The study investigated ChromaDex’s proprietary Niagen^® ingredient (patented nicotinamide riboside, or “NR”) in patients with ataxia-telangiectasia (AT), a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition. The study found that supplementation with NR improved ataxia scores and increased immunoglobulins, or antibodies, in the immune-compromised patients. In addition to the findings, this was the first published clinical NR trial to include participants under the age of 18, examining the potential impact NR might have in children with AT.

“AT is a condition where children experience the negative effects of premature aging with a very limited life expectancy,” said Dr. Andrew Shao, ChromaDex Senior Vice President of Global Scientific & Regulatory Affairs. “The results of this study are promising for those living with AT and are consistent with previous preclinical research. We look forward to the continued clinical research exploring the impact of Niagen^® on age-related health declines.”

This study included 24 AT patients (15 males, 9 females), and 17 of the 24 were children under 18. The patients’ average age was 17.5 and no one in the study had previously supplemented with NR. The group received 25mg/kg body weight of NR per day for four consecutive months, followed by a two-month period without NR treatment. The effects of NR on ataxia (a group of disorders that affect coordination, balance and speech), dysarthria (a motor speech disorder), quality of life, and laboratory parameters were analyzed.

NR improved ataxia scores in patients and increased serum immunoglobulin G (IgG), or antibodies, which are important for protection against pathogens. Patients with AT are known to be immunodeficient with decreased serum immunoglobulins concentrations.

These results suggest that NAD⁺ boosting may be a potential therapeutic strategy for AT, however further research needs to be conducted.

For additional information on the science supporting Niagen^® visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen^®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements related to results of the clinical studies, their significance and potential impact of NR on those living with AT. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005169/en/

ChromaDex Media Contact:

Alex Worsham, Vice President of Global Marketing & Communications

310-388-6706 ext. 689

alexw@chromadex.com

ChromaDex Investor Relations Contact:

Brianna Gerber, Vice President of Finance and Investor Relations

949-419-0288 ext. 127

briannag@chromadex.com

Source: ChromaDex Corporation

FAQ

What were the findings of the clinical study on CDXC's NR for ataxia-telangiectasia?

The study found that nicotinamide riboside (NR) improved ataxia scores and increased immunoglobulin levels in AT patients.

How many patients were involved in the CDXC NR clinical study?

The study included 24 patients with ataxia-telangiectasia, of which 17 were children under 18.

What dosage of NR was administered in the study conducted by ChromaDex?

Patients received a dosage of 25mg/kg body weight of nicotinamide riboside (NR) per day for four months.

What is the significance of the study published in Movement Disorders for CDXC?

This study is the first published clinical trial of NR, indicating its potential as a therapeutic strategy for ataxia-telangiectasia.

What are the next steps for ChromaDex following the NR clinical study results?

ChromaDex plans to continue clinical research to further explore the impact of NR on age-related health declines.